Ralliant Corporation (NYSE:RAL – Get Free Report) CEO Tamara Newcombe sold 12,936 shares of Ralliant stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $71.79, for a total transaction of $928,675.44. Following the sale, the chief executive officer directly owned 251,967 shares of the company’s stock, valued at $18,088,710.93. The trade was a 4.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ralliant Stock Performance
RAL traded down $2.54 on Tuesday, reaching $69.42. The company had a trading volume of 1,336,205 shares, compared to its average volume of 1,694,804. The stock has a market cap of $7.68 billion, a P/E ratio of -6.40, a P/E/G ratio of 2.69 and a beta of 1.61. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The company’s fifty day moving average is $68.82 and its 200 day moving average is $55.58.
Ralliant (NYSE:RAL – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The firm had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, analysts predict that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.
Ralliant Announces Dividend
Institutional Investors Weigh In On Ralliant
Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Ralliant during the second quarter worth approximately $1,039,481,000. Viking Global Investors LP acquired a new position in Ralliant in the 2nd quarter valued at $257,200,000. State Street Corp bought a new stake in shares of Ralliant during the 2nd quarter valued at $213,096,000. Millennium Management LLC grew its holdings in shares of Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after purchasing an additional 3,147,660 shares in the last quarter. Finally, Flossbach Von Storch SE acquired a new stake in shares of Ralliant during the 2nd quarter worth $222,460,000.
Wall Street Analyst Weigh In
Several analysts recently issued reports on RAL shares. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a research note on Friday, July 31st. Truist Financial reiterated a “buy” rating and set a $82.00 price objective (up from $68.00) on shares of Ralliant in a research report on Friday, July 31st. Zacks Research raised Ralliant from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 30th. Wall Street Zen cut shares of Ralliant from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 11th. Finally, Oppenheimer upped their price target on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $75.70.
View Our Latest Research Report on RAL
Ralliant Company Profile
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
See Also
- Five stocks we like better than Ralliant
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
